MARK ENGELSTAD: Open Payments
NPI 1619914447 · WESTMINSTER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$836 in 47 payments from 18 companies in 2025. Trend: 2023 $1,381 · 2024 $1,246 · 2025 $836
Food & beverage: $836
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $151 |
| Lilly USA, LLC | 7 | $119 |
| PFIZER INC. | 4 | $86 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $84 |
| Astellas Pharma US Inc | 3 | $55 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| Novo Nordisk Inc | 2 | $37 |
| Cranial Technologies, Inc | 2 | $37 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $36 |
| Edwards Lifesciences Corporation | 1 | $30 |
Products named: JARDIANCE, VRAYLAR, MOUNJARO, Veozah, NURTEC ODT, Ozempic, Doc Band, Kerendia.
Industry payments across CO — which companies pay providers there.
